Interstitial lung diseases

M Wijsenbeek, A Suzuki, TM Maher - The Lancet, 2022 - thelancet.com
Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

PM George, AU Wells, RG Jenkins - The Lancet Respiratory …, 2020 - thelancet.com
In December, 2019, reports emerged from Wuhan, China, of a severe acute respiratory
disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). By the …

Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline

G Raghu, M Remy-Jardin, L Richeldi… - American Journal of …, 2022 - atsjournals.org
Background: This American Thoracic Society, European Respiratory Society, Japanese
Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior …

[HTML][HTML] Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation

LE Leard, AM Holm, M Valapour, AR Glanville… - The Journal of Heart and …, 2021 - Elsevier
Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …

J Behr, A Prasse, M Kreuter, J Johow… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Spectrum of fibrotic lung diseases

M Wijsenbeek, V Cottin - New England Journal of Medicine, 2020 - Mass Medical Soc
Pulmonary Fibrotic Diseases This review covers fibrotic pulmonary diseases. Although
idiopathic pulmonary fibrosis is very common, the review focuses mainly on fibrotic diseases …

Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities

PM George, P Spagnolo, M Kreuter… - The lancet Respiratory …, 2020 - thelancet.com
Within the spectrum of fibrosing interstitial lung diseases (ILDs) is a subset of patients who
have inexorable progression of pulmonary fibrosis despite treatment, which is known as the …

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled …

JJ Solomon, SK Danoff, FA Woodhead… - The Lancet …, 2023 - thelancet.com
Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of develo** the disease in any individual of 7· 7%. We aimed to assess the …

Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management

S Kadura, G Raghu - European Respiratory Review, 2021 - Eur Respiratory Soc
Rheumatoid arthritis (RA) is a systemic inflammatory disorder, with the most common extra-
articular manifestation of RA being lung involvement. While essentially any of the lung …

Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies

I Lurje, NT Gaisa, R Weiskirchen, F Tacke - Molecular Aspects of Medicine, 2023 - Elsevier
Fibrosis, or tissue scarring, develops as a pathological deviation from the physiological
wound healing response and can occur in various organs such as the heart, lung, liver …